234 filings
Page 4 of 12
8-K
9xgk ewsxnxnw80t614
21 Jun 19
Departure of Directors or Certain Officers
4:06pm
8-K
l8n3jkc0
18 Jun 19
Casi Pharmaceuticals Acquires Worldwide Rights to Commercialize ANTI-CD19 T-cell Therapy
4:01pm
8-K
j2jjdanypicbe
15 May 19
Casi Pharmaceuticals Announces First Quarter 2019
9:00am
8-K
nhrrvpxqay oekt
17 Apr 19
Entry into a Material Definitive Agreement
4:03pm
8-K
6syasofvzm779d9mh
5 Apr 19
Casi Pharmaceuticals Announces the Appointment of Wei-wu He, PH.D., Executive Chairman, to the Role of Chief Executive Officer
4:31pm
8-K
j2bcu 2baat
29 Mar 19
Full Year 2018 Financial Results and Business Results
9:00am
8-K
4f1g9y n4lt1n
13 Mar 19
Casi Pharmaceuticals Announces Exclusive Distribution Partner for Melphalan Hydrochloride for Injection (Evomela®) In China
5:18pm
8-K
2azii0ls3e rqh
19 Feb 19
Other Events
5:23pm
8-K
vx5ull36695
29 Jan 19
Changes in Registrant's Certifying Accountant
4:46pm
8-K
7xno4x
6 Dec 18
Casi Pharmaceuticals Announces China Market Approval
4:30pm
8-K
9bji5j968y
20 Nov 18
Entry into a Material Definitive Agreement
5:07pm
8-K
7c08zmokqz70k6j837p
14 Nov 18
Casi Pharmaceuticals Announces Third Quarter and First Nine Months
9:02am
8-K/A
kq188d i23ahrloy533q
24 Oct 18
Departure of Directors or Certain Officers
5:02pm
8-K
hnenx qy2
24 Oct 18
Casi Pharmaceuticals Acquires HBV Anda
4:57pm
8-K
i29zk0u7
28 Sep 18
Casi Pharmaceuticals Announces Appointment of Chief Financial Officer
8:13pm
8-K
b0eqqdxeg
27 Sep 18
Changes in Registrant's Certifying Accountant
8:13pm
8-K
mmj424ifolo rm3v
14 Sep 18
Casi Pharmaceuticals Announces $48.5 Million Private Placement
12:00am
8-K
n7so04yyurz6cb67g
14 Aug 18
Casi Pharmaceuticals Announces Second Quarter and First Half 2018 Financial and Business Results
9:00am
8-K
lqoowmmk kr
11 Jun 18
Departure of Directors or Certain Officers
5:17pm
8-K
l18qm2l503
15 May 18
Casi Pharmaceuticals Announces First Quarter 2018
9:00am